The Fraunhofer Institute in Germany has now developed two techniques that could make testing faster and cheaper.
Category:
Apparatus
-
-
Biopharmaceutical company Airway has announced that the first patient will be administered AT-100 (rhSP-D) in a phase 1b randomised trial to prevent the risk of bronchopulmonary dysplasia (BPD) in very preterm infants. The novel prophylactic AT-100 reduces the incidence and severity of the severe respiratory disease BPD and may improve the prognosis of very preterm infants.
-
The global ADC drug market will be approximately $5.2 billion by 2021
-
HBM1020 is the world's first anti-B7H7 monoclonal antibody to be formally approved for clinical phase.
-
Apparatus
Nature Medicine publishes results of H-drug combined with chemotherapy for first-line treatment of esophageal squamous cell carcinoma
H-Drugs in the leading international journal again!
-
New therapy for lung cancer!
-
The FDA has granted accelerated approval to Adagrasib for the treatment of patients with KRAS G12C mutations in non-small cell lung cancer. In the trial, the drug resulted in disease control in 80% of patients, of which, 43% had substantial tumour shrinkage.
-
Apparatus
Acs Med. Chem. Lett.| Protac-Targeted Jak2 Protein Kinase: a New Approach To Cancer Therapy
A new approach to cancer treatment!
-
Apparatus
The "hand speed" is extremely fast, and scientists create a DNA robot arm that can move at a high speed
DNA nano robot system is one of the nano machines, and has been continuously developed in recent years. In recent years, in the journal Science, we saw another "feat" realized by DNA nano robot - researchers used electric field to accelerate the movement speed of DNA robot system.
-
Apparatus
FDA Grants Orphan Drug Status To Two New Therapies In a Row, And These Two Groups Of Patients Are Expected To Benefit!
Recently, the US FDA has granted orphan drug status to two new therapeutics in a row. One is a small molecule inhibitor, PCLX-001, for the treatment of acute myeloid leukaemia; the other is a T-cell therapy, ET140203, for the treatment of hepatoblastoma. Both therapies are currently in relevant trials.
